As many people consider lifestyle changes at the start of the year, the Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they use are safe, effective and legitimate.
Similar Posts
MHRA statement on new review of paracetamol safety during pregnancy
Paracetamol should be taken as directed in the patient information leaflet.
Guidance: Centres of Excellence for Regulatory Science and Innovation (CERSIs)
An initiative to help drive advancements in healthcare, to ensure patients benefit from innovation and new treatments sooner.
If you take a GLP-1 medicine and have been hospitalised by acute pancreatitis, the Yellow Card Biobank wants to hear from you
GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro and Wegovy
Aurum pre-filled syringes phased introduction of new 10ml CONNECT syringe barrel: Importance of selecting compatible needle-free connectors to minimise the risk of syringe blockage (DSI/2025/02)
Due to a phased introduction of the new 10ml CONNECT barrel design for the Aurum pre-filled syringes, the range of compatible needle free connectors (NFCs) differs between the established syringe barrel and the new syringe barrel. It is vital that healthcare professionals use compatible NFCs with Aurum pre-filled syringes to prevent delays to delivery of emergency medication.
MHRA welcomes Professor Jonathan Benger CBE as new CEO of NICE
Professor Benger’s leadership comes at a pivotal time as the MHRA and NICE deepen collaboration
Standard: Category lists following implementation of the Windsor Framework
A list of individual human medicinal products under the new arrangements coming into effect on 1 January 2025 following agreement of the Windsor Framework.